A Fast LC/MS/MS method for Determination of Telmisartan in Human Plasma by LC-MS-MS

Importance of the topic

Accurate and rapid quantification of telmisartan in human plasma is essential for pharmacokinetic studies, therapeutic drug monitoring and bioequivalence assessments. The development of robust LC-MS/MS assays improves sensitivity and throughput while minimizing sample preparation complexity.

Objectives and overview of the study

This study aimed to establish a fast and reliable UHPLC-MS/MS method for measuring telmisartan levels in human plasma. Key goals included achieving a low limit of quantitation (LLOQ), broad linear dynamic range and high reproducibility using a simple protein precipitation extraction.

Methodology and instrumentation

A straightforward sample preparation protocol involved:

• Spiking 180 µL plasma with internal standard (irbesartan) and standards.
• Protein precipitation with 1,000 µL ice-cold acetonitrile.
• Centrifugation at 10,000 rpm for 10 minutes and direct injection of supernatant.

The chromatographic and mass spectrometric setup included:

• UHPLC Nexera system.
• Shimadzu LCMS-8040 triple quadrupole mass spectrometer with ESI source.
• Zorbax Eclipse Plus C18 column (100×2.1 mm, 1.8 µm).
• Isocratic mobile phase: 0.02 M ammonium acetate / acetonitrile (60:40 v/v) at 600 µL/min.
• MRM transitions: m/z 515→276 for telmisartan and m/z 429→207 for irbesartan.

Main results and discussion

The method demonstrated:

• LLOQ of 4 ng/mL with CV <20% at the lowest level.
• Linear calibration from 4 to 2,000 ng/mL (R²=0.997).
• Intra- and inter-day precision (%CV) of 3.6–5.3% across low, mid and high QC levels.
• Accuracy (bias) within 85–103% of nominal concentrations.
• Recovery of telmisartan from plasma extract between 85.9% and 101.4%.

Benefits and practical application of the method

This approach delivers high throughput and minimal sample handling, making it ideal for large-scale pharmacokinetic and bioequivalence trials. The sensitive detection range supports both low-dose monitoring and high-concentration sample analysis.

Future trends and possibilities for application

Emerging directions include integration with high-resolution mass spectrometry for enhanced selectivity, automation of sample preparation to further boost throughput, and multiplexed assays to quantify multiple antihypertensive agents in a single run.

Conclusion

A rapid, sensitive and reproducible UHPLC-MS/MS method for telmisartan in human plasma was successfully developed. The assay meets regulatory requirements for precision, accuracy and linearity while employing a simple extraction protocol.

Reference

• Venkateswaran M., Pillai S.L., Manohar V., Thyagarajan A. A Fast LC/MS/MS Method for Determination of Telmisartan in Human Plasma by LC-MS/MS. Application AD-0072, Shimadzu, 2014.